Since these molecules are both homologous substances, gastrin-releasing peptide can be postulated to exert effects similar to neuromedin B. Previous studies have not found a relationship between serum neuromedin B levels and MCI or AD status; we here first report that serum neuromedin B levels effectively distinguish HC from aMCI patients. This evidence concerns the gene NMB and Alzheimer disease.